Transcriptomic profiling of different responder types in adults after a Priorix\uae vaccination

Abstract: Thanks to the recommendation of a combined Measles/Mumps/Rubella (MMR) vaccine, like Priorix\uae, these childhood diseases are less common now. This is beneficial to limit the spread of these diseases and work towards their elimination. However, the measles, mumps and rubella antibody titers show a large variability in short- and long-term immunity. The recent outbreaks worldwide of measles and mumps and previous studies, which mostly focused on only one of the three virus responses, illustrate that there is a clear need for better understanding the immune responses after vaccination. Our healthy cohort was already primed with the MMR antigens in their childhood. In this study, the adult volunteers received one Priorix\uae vaccine dose at day 0. First, we defined 4 different groups of responders, based on their antibody titers\u2019 evolution over 4 time points (Day 0, 21, 150 and 365). This showed a high variability within and between individuals. Second, we determined transcriptome profiles using 3\u2032mRNA sequencing at day 0, 3 and 7. Using two analytical approaches, \u201cone response group per time point\u201d and \u201ca time comparison per response group\u201d, we correlated the short-term gene expression profiles to the different response groups. In general, the list of differentially expressed genes is limited, however, most of them are clearly immune-related and upregulated at day 3 and 7, compared to the baseline day 0. Depending on the specific response group there are overlapping signatures for two of the three viruses. Antibody titers and transcriptomics data showed that an additional Priorix vaccination does not facilitate an equal immune response against the 3 viruses or among different vaccine recipients